HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: jcp.2007.052100v1 61/5/677    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Google Scholar Articles by Williams, C Articles by Neylon, A J PubMed PubMed Citation Articles by Williams, C Articles by Neylon, A J Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Brain Diseases Eosinophilic Disorders Hazardous Substances DB IMATINIB MESYLATE

FIP1L1–PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement

¹ Department of Haematology, Newcastle Hospitals Trust, Newcastle upon Tyne, UK
² Regional Neurosciences Unit, Newcastle Hospitals Trust, Newcastle upon Tyne, UK
³ NHS Northern Genetics Service, Newcastle upon Tyne, UK
⁴ Department of Histopathology, Newcastle Hospitals Trust, Newcastle upon Tyne, UK
⁵ Department of Haematology, City Hospitals Sunderland Trust, Sunderland, UK

Correspondence to:
Dr Chris Williams, Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK; cdwilliams26{at}blueyonder.co.uk

ABSTRACT
Interstitial deletion involving chromosome 4q12 generates the novel tyrosine kinase fusion protein encoded by FIP1L1–PDGFRA, which is present in many patients previously labelled as having hypereosinophilic syndrome, initially reported in 2003. Reports in recent literature document excellent clinical and molecular response to the tyrosine kinase inhibitor imatinib (Glivec). This report describes the case of a 58-year-old lady, diagnosed with FIP1L1–PDGFRA positive hypereosinophilic disorder, who subsequently developed symptoms related to an intracranial lesion. Biopsy and molecular genetic studies confirmed a diffuse infiltrative lesion, with evidence of FIP1L1–PDGFRA gene fusion. Initiation of imatinib treatment led to impressive clinical and radiological response.